On May 13, 2025, Affimed (AFMD, Financial) experienced a notable shift in its stock rating as Wells Fargo analyst Yanan Zhu downgraded the company from a previous "Overweight" to "Equal-Weight". This change reflects a reassessment of the company's market performance and future potential.
In addition to the rating downgrade, Wells Fargo dramatically lowered the price target for Affimed (AFMD, Financial) from $11.00 to a mere $0.10. This significant reduction represents a staggering 99.09% decrease, highlighting a substantial change in the analyst's expectations and outlook for the company's future valuation.
The adjustment in the price target and rating comes at a time when the market is closely observing Affimed's (AFMD, Financial) strategic moves and financial health. Investors interested in Affimed should closely monitor subsequent analyses and reports for further insights into the company's performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Affimed NV (AFMD, Financial) is $11.79 with a high estimate of $24.57 and a low estimate of $4.91. The average target implies an upside of 8,699.72% from the current price of $0.13. More detailed estimate data can be found on the Affimed NV (AFMD) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Affimed NV's (AFMD, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Affimed NV (AFMD, Financial) in one year is $0.37, suggesting a upside of 176.12% from the current price of $0.134. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Affimed NV (AFMD) Summary page.
